X線共結晶解析に基づく高活性かつ高選択的な非亜鉛結合型MMP-13阻害薬の分子設計と合成

1.

Yoshimura, N.; Muraki, S.; Oka, H.; Mabuchi, A.; En-Yo, Y.; Yoshida, M.; Saika, A.; Yoshida,

H.; Suzuki, T.; Yamamoto, S.; Ishibashi, H.; Kawaguchi, H.; Nakamura, K.; Akune, T. Prevalence of knee

osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on

osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 2009, 27, 620-8.

2.

Couzin, J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science

2004, 306, 384-5.

3.

FitzGerald, G. A. Coxibs and Cardiovascular Disease. N Engl J Med 2004, 351, 1709-1711.

4.

Zhang, W.; Ouyang, H.; Dass, C. R.; Xu, J. Current research on pharmacologic and regenerative

therapies for osteoarthritis. Bone Res 2016, 4, 15040.

5.

Sophia Fox, A. J.; Bedi, A.; Rodeo, S. A. The basic science of articular cartilage: structure,

composition, and function. Sports Health 2009, 1, 461-8.

6.

Horkay, F. Interactions of Cartilage Extracellular Matrix Macromolecules. J Polym Sci B Polym

Phys 2012, 50, 1699-1705.

7.

Hardin, J. A.; Cobelli, N.; Santambrogio, L. Consequences of metabolic and oxidative

modifications of cartilage tissue. Nat Rev Rheumatol 2015, 11, 521-9.

8.

Nagase, H.; Woessner, J. F., Jr. Matrix metalloproteinases. J Biol Chem 1999, 274, 21491-4.

9.

Visse, R.; Nagase, H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases:

structure, function, and biochemistry. Circ Res 2003, 92, 827-39.

10.

Gross, J.; Lapiere, C. M. Collagenolytic activity in amphibian tissues: a tissue culture assay.

Proc Natl Acad Sci U S A 1962, 48, 1014-22.

11.

Fullmer, H. M.; Gibson, W. Collagenolytic activity in gingivae of man. Nature 1966, 209, 728-9.

12.

Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. Design and therapeutic application of

matrix metalloproteinase inhibitors. Chem Rev 1999, 99, 2735-76.

13.

Mitchell, P. G.; Magna, H. A.; Reeves, L. M.; Lopresti-Morrow, L. L.; Yocum, S. A.; Rosner, P.

J.; Geoghegan, K. F.; Hambor, J. E. Cloning, expression, and type II collagenolytic activity of matrix

metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996, 97, 761-8.

14.

Reboul, P.; Pelletier, J. P.; Tardif, G.; Cloutier, J. M.; Martel-Pelletier, J. The new collagenase,

collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in

osteoarthritis. J Clin Invest 1996, 97, 2011-9.

15.

Bau, B.; Gebhard, P. M.; Haag, J.; Knorr, T.; Bartnik, E.; Aigner, T. Relative messenger RNA

expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in

vitro. Arthritis Rheum 2002, 46, 2648-57.

103

16.

Matsushita, T.; Sasaki, H.; Takayama, K.; Ishida, K.; Matsumoto, T.; Kubo, S.; Matsuzaki, T.;

Nishida, K.; Kurosaka, M.; Kuroda, R. The overexpression of SIRT1 inhibited osteoarthritic gene

expression changes induced by interleukin-1beta in human chondrocytes. J Orthop Res 2013, 31, 531-7.

17.

Knauper, V.; Lopez-Otin, C.; Smith, B.; Knight, G.; Murphy, G. Biochemical characterization of

human collagenase-3. J Biol Chem 1996, 271, 1544-50.

18.

Mitchell, P. G.; Magna, H. A.; Reeves, L. M.; Lopresti-Morrow, L. L.; Yocum, S. A.; Rosner, P.

J.; Geoghegan, K. F.; Hambor, J. E. Cloning, expression, and type II collagenolytic activity of matrix

metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996, 97, 761-768.

19.

Neuhold, L. A.; Killar, L.; Zhao, W.; Sung, M. L.; Warner, L.; Kulik, J.; Turner, J.; Wu, W.;

Billinghurst, C.; Meijers, T.; Poole, A. R.; Babij, P.; DeGennaro, L. J. Postnatal expression in hyaline

cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice. J Clin

Invest 2001, 107, 35-44.

20.

Little, C. B.; Barai, A.; Burkhardt, D.; Smith, S. M.; Fosang, A. J.; Werb, Z.; Shah, M.;

Thompson, E. W. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage

erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60, 3723-33.

21.

Vankemmelbeke, M.; Dekeyser, P. M.; Hollander, A. P.; Buttle, D. J.; Demeester, J.

Characterization of helical cleavages in type II collagen generated by matrixins. Biochem J 1998, 330 ( Pt

2), 633-40.

22.

Knäuper, V.; López-Otin, C.; Smith, B.; Knight, G.; Murphy, G. Biochemical Characterization of

Human Collagenase-3. J. Biol. Chem. 1996, 271, 1544-1550.

23.

Rousseau, J. C.; Delmas, P. D. Biological markers in osteoarthritis. Nat Clin Pract Rheumatol

2007, 3, 346-56.

24.

Bode, W.; Fernandez-Catalan, C.; Tschesche, H.; Grams, F.; Nagase, H.; Maskos, K. Structural

properties of matrix metalloproteinases. Cell Mol Life Sci 1999, 55, 639-52.

25.

Bode, W.; Gomis-Rüth, F. X.; Stöckler, W. Astacins, serralysins, snake venom and matrix

metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and

topologies and should be grouped into a common family, the 'metzincins'. FEBS Lett 1993, 331, 134-40.

26.

Murphy, G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer

2008, 8, 929-41.

27.

Massova, I.; Kotra, L. P.; Mobashery, S. Structural insight into the binding motifs for the

calcium ion and the non-catalytic zinc in matrix metalloproteases. Bioorg Med Chem Lett 1998, 8, 853-8.

28.

Aureli, L.; Gioia, M.; Cerbara, I.; Monaco, S.; Fasciglione, G. F.; Marini, S.; Ascenzi, P.; Topai,

A.; Coletta, M. Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. Curr

Med Chem 2008, 15, 2192-222.

29.

Cerdà-Costa, N.; Gomis-Rüth, F. X. Architecture and function of metallopeptidase catalytic

104

domains. Protein Sci 2014, 23, 123-44.

30.

Jacobsen, J. A.; Major Jourden, J. L.; Miller, M. T.; Cohen, S. M. To bind zinc or not to bind

zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys

Acta 2010, 1803, 72-94.

31.

Devel, L.; Czarny, B.; Beau, F.; Georgiadis, D.; Stura, E.; Dive, V. Third generation of matrix

metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity. Biochimie 2010, 92,

1501-8.

32.

Matter, H.; Schudok, M. Recent advances in the design of matrix metalloprotease inhibitors.

Curr Opin Drug Discov Devel 2004, 7, 513-35.

33.

Hoekstra, R.; Eskens, F. A.; Verweij, J. Matrix metalloproteinase inhibitors: current

developments and future perspectives. Oncologist 2001, 6, 415-427.

34.

Reiter, L. A.; Robinson, R. P.; McClure, K. F.; Jones, C. S.; Reese, M. R.; Mitchell, P. G.;

Otterness, I. G.; Bliven, M. L.; Liras, J.; Cortina, S. R.; Donahue, K. M.; Eskra, J. D.; Griffiths, R. J.;

Lame, M. E.; Lopez-Anaya, A.; Martinelli, G. J.; McGahee, S. M.; Yocum, S. A.; Lopresti-Morrow, L. L.;

Tobiassen, L. M.; Vaughn-Bowser, M. L. Pyran-containing sulfonamide hydroxamic acids: potent MMP

inhibitors that spare MMP-1. Bioorg Med Chem Lett 2004, 14, 3389-3395.

35.

Peterson, J. T. The importance of estimating the therapeutic index in the development of matrix

metalloproteinase inhibitors. Cardiovasc Res 2006, 69, 677-687.

36.

Vandenbroucke, R. E.; Libert, C. Is there new hope for therapeutic matrix metalloproteinase

inhibition? Nat Rev Drug Discov 2014, 13, 904-27.

37.

Lovejoy, B.; Welch, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.;

Walker, K. A.; Martin, R.; Van Wart, H.; Browner, M. F. Crystal structures of MMP-1 and -13 reveal the

structural basis for selectivity of collagenase inhibitors. Nat Struct Biol 1999, 6, 217-221.

38.

Andrianjara, C.; Ortwine, D., Fred; Pavlovsky, A., Gregory; Roark, W., Howard. Matrix

Metalloproteinase Inhibitors. WO2002064080.

39.

Terauchi, J.; Kuno, H.; Nara, H.; Oki, H.; Sato, K. Preparation of heterocyclic amides as MMP-

13 inhibitors for treating osteoarthritis and rheumatoid arthritis. WO2005105760A1, 2005.

40.

Nara, H.; Sato, K.; Kaieda, A.; Oki, H.; Kuno, H.; Santou, T.; Kanzaki, N.; Terauchi, J.;

Uchikawa, O.; Kori, M. Design, synthesis, and biological activity of novel, potent, and highly selective

fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.

Bioorg Med Chem 2016, 24, 6149-6165.

41.

Nara, H.; Sato, K.; Naito, T.; Mototani, H.; Oki, H.; Yamamoto, Y.; Kuno, H.; Santou, T.;

Kanzaki, N.; Terauchi, J.; Uchikawa, O.; Kori, M. Discovery of novel, highly potent, and selective

quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding

group using a structure-based design approach. J Med Chem 2014, 57, 8886-8902.

105

42.

Sellstedt, J. H.; Guinosso, C. J.; Begany, A. J.; Bell, S. C.; Rosenthale, M. Oxanilic acids, a new

series of orally active antiallergic agents. J. Med. Chem. 1975, 18, 926-933.

43.

Sugiyama, Y.; Sasaki, T.; Nagato, N. Acid-catalyzed reaction of ethyl cyanoformate with

aromatic amines in acetic acid: facile synthesis of N-substituted amidinoformic acids and ethyl 4quinazolone-2-carboxylate. J. Org. Chem. 1978, 43, 4485-4487.

44.

Behar, V.; Danishefsky, S. J. Total synthesis of the novel benzopentathiepin varacinium

trifluoroacetate: the viability of "varacin-free base". J. Am. Chem. Soc. 1993, 115, 7017-7018.

45.

Carretero, J. C.; Garcia Ruano, J. L.; Vicioso, M. A practical route to C-8 substituted

fluoroquinolones. Tetrahedron 1992, 48, 7373-7382.

46.

Nicholson, G.; Silversides, J. D.; Archibald, S. J. Routes to highly substituted thiophenol

derivatives. Tetrahedron Letters 2006, 47, 6541-6544.

47.

Ballard, P.; Bradbury, R. H.; Hennequin, L. F. A.; Hickinson, D. M.; Johnson, P. D.; Kettle, J.

G.; Klinowska, T.; Morgentin, R.; Ogilvie, D. J.; Olivier, A. 5-Substituted 4-anilinoquinazolines as potent,

selective and orally active inhibitors of erbB2 receptor tyrosine kinase. Bioorganic & Medicinal

Chemistry Letters 2005, 15, 4226-4229.

48.

Webber, S., E.; Bleckman, T., M. ; Attard, J.; Jones, T., R.; Varney, M., D. Antiproliferative

Quinazolines. WO1993020055.

49.

Sabeh, F.; Li, X. Y.; Saunders, T. L.; Rowe, R. G.; Weiss, S. J. Secreted versus membrane-

anchored collagenases: relative roles in fibroblast-dependent collagenolysis and invasion. J Biol Chem

2009, 284, 23001-11.

50.

The structure of side product was speculated to be the tricyclic compound I.

51.

Abbenante, G.; Fairlie, D. P. Protease inhibitors in the clinic. Med Chem 2005, 1, 71-104.

52.

Cawston, T. E.; Ellis, A. J.; Humm, G.; Lean, E.; Ward, D.; Curry, V. Interleukin-1 and

oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in

culture. Biochemical and Biophysical Research Communications 1995, 215, 377-85.

53.

Bottomley, K. M.; Borkakoti, N.; Bradshaw, D.; Brown, P. A.; Broadhurst, M. J.; Budd, J. M.;

Elliott, L.; Eyers, P.; Hallam, T. J.; Handa, B. K.; Hill, C. H.; James, M.; Lahm, H. W.; Lawton, G.;

Merritt, J. E.; Nixon, J. S.; Rothlisberger, U.; Whittle, A.; Johnson, W. H. Inhibition of bovine nasal

cartilage degradation by selective matrix metalloproteinase inhibitors. Biochemical Journal 1997, 323 ( Pt

2), 483-8.

54.

Guingamp, C.; Gegout-Pottie, P.; Philippe, L.; Terlain, B.; Netter, P.; Gillet, P. Mono-

iodoacetate-induced experimental osteoarthritis: a dose-response study of loss of mobility, morphology,

and biochemistry. Arthritis and Rheumatism 1997, 40, 1670-9.

55.

Janusz, M. J.; Hookfin, E. B.; Heitmeyer, S. A.; Woessner, J. F.; Freemont, A. J.; Hoyland, J. A.;

Brown, K. K.; Hsieh, L. C.; Almstead, N. G.; De, B.; Natchus, M. G.; Pikul, S.; Taiwo, Y. O. Moderation

106

of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors.

Osteoarthritis and Cartilage 2001, 9, 751-60.

56.

Janusz, M. J.; Little, C. B.; King, L. E.; Hookfin, E. B.; Brown, K. K.; Heitmeyer, S. A.;

Caterson, B.; Poole, A. R.; Taiwo, Y. O. Detection of aggrecanase- and MMP-generated catabolic

neoepitopes in the rat iodoacetate model of cartilage degeneration. Osteoarthritis and Cartilage 2004, 12,

720-8.

57.

Lohmander, L. S.; Atley, L. M.; Pietka, T. A.; Eyre, D. R. The release of crosslinked peptides

from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis.

Arthritis and Rheumatism 2003, 48, 3130-9.

58.

Oestergaard, S.; Chouinard, L.; Doyle, N.; Karsdal, M. A.; Smith, S. Y.; Qvist, P.; Tanko, L. B.

The utility of measuring C-terminal telopeptides of collagen type II (CTX-II) in serum and synovial fluid

samples for estimation of articular cartilage status in experimental models of destructive joint diseases.

Osteoarthritis Cartilage 2006, 14, 670-9.

59.

Hennequin, L. F.; Boyle, F. T.; Wardleworth, J. M.; Marsham, P. R.; Kimbell, R.; Jackman, A. L.

Quinazoline Antifolates Thymidylate Synthase Inhibitors: Lipophilic Analogues with Modification to the

C2-Methyl Substituent. J. Med. Chem. 1996, 39, 695-704.

60.

Gilman, H.; Melstrom, D. S. Organolithium Compounds with Hydroxyl, Nitrilo and

Sulfonamido Groups. J. Am. Chem. Soc. 1948, 70, 4177-4179.

61.

Hayashi, T.; Kagawa, M. Reactions of Acetoin and Benzoin with Malononitrile. Bull. Chem.

Soc. Jpn. 1970, 43, 3290.

62.

Dumaitre, B.; Dodic, N. Synthesis and Cyclic GMP Phosphodiesterase Inhibitory Activity of a

Series of 6-Phenylpyrazolo[3,4-d]pyrimidones. J. Med. Chem. 1996, 39, 1635-1644.

63.

Cheng, C. C.; Robins, R. K. Potential Purine Antagonists. VI. Synthesis of 1-Alkyl- and 1-Aryl-

4-substituted Pyrazolo[3,4-d]pyrimidines. J. Org. Chem. 1956, 21, 1240-1256.

64.

Barker, J. M.; Huddleston, P. R.; Wood, M. L. A rapid conversion of 3-oxothiolanes into 3-

aminothiophenes. Synthetic Communications 2002, 32, 2565-2568.

65.

Toja, E.; Tarzia, G.; Ferrari, P.; Tuan, G. Pyrrolopyridine Analogs of Nalidixic Acid. 1.

Pyrrolo[2,3-b]pyridines. J. Heterocycl. Chem. 1986, 23, 1555-1560.

66.

Temple, D. L.; Yevich, J. P.; Covington, R. R.; Hanning, C. A.; Seidehamel, R. J.; Mackey, H.

K.; Bartek, M. J. Synthesis of 3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylates, a new series of

orally active antiallergy agents. J. Med. Chem. 1979, 22, 505-510.

67.

Temple, J., Davis L. Thieno[2,3-d]pyrimidine antiallergic agents. US4054656.

68.

Miyashita, A.; Fujimoto, K.; Okada, T.; Higashino, T. Synthesis of Fused Pyrimidinones by

Reaction of Aminoarenecarboxamide with Esters; Preparation of Pyrrolo[2,3-d]-, Thieno[2,3-d]-,

Isoxazolo[5,4-d]-, and 1,2,3-Triazolo[4,5-d]-pyrimidinones, and Quinazolones. Heterocycles 1996, 42,

107

691-699.

69.

Sato, H.; Kinoshita, T.; Takino, T.; Nakayama, K.; Seiki, M. Activation of a recombinant

membrane type 1-matrix metalloproteinase (MT1-MMP) by furin and its interaction with tissue inhibitor

of metalloproteinases (TIMP)-2. FEBS Letters 1996, 393, 101-104.

70.

Vagin, A.; Teplyakov, A. MOLREP: an Automated Program for Molecular Replacement. Journal

of Applied Crystallography 1997, 30, 1022-1025.

71.

The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr

1994, 50, 760-763.

72.

Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot. Acta

Crystallographica Section D 2010, 66, 486-501.

73.

Otwinowski, Z.; Minor, W. Processing of X-ray diffraction data collected in oscillation mode. In

Methods in Enzymology, Charles W. Carter, Jr., Ed. Academic Press: 1997; Vol. Volume 276, pp 307-326.

108

謝辞

本稿を完成するにあたり、終始ご指導ご鞭撻を賜りました、東京大学大学院薬学系研究科分子

薬学専攻生物有機化学講座、薬品代謝化学教室教授浦野泰照先生に深く感謝いたします。

原稿を注意深く読んで下さり、終始、多くの有益なご助言や温かいご支援をいただきました、

長展生博士に深く感謝いたします。

本研究は、武田薬品工業株式会社において実施したもので、X 線構造解析のためのヒト MMP13 の触媒ドメインの作成について大前弘明氏、田中陽子氏、NMR 測定によるヒット化合物の同

定について村林美香氏、遠藤聡史博士、髙木輝文氏、結晶学的研究を支援して頂いた藤嶋聡氏に

感謝いたします。

本研究を通じて貴重なご議論をいただいた大川滋紀博士、石原雄二博士、池浦義典博士、瀧澤

正之博士、神山圭司博士、吉松賢太郎博士に感謝いたします。

重要な化合物の調製や、実りある議論をいただいた海江田啓氏に感謝いたします。

本論文の執筆にあたり、分子化学計算で協力、議論をいただいた奈良禎氏に感謝いたします。

本論文の執筆にあたり、有用なご助言を頂きました前﨑博信博士に感謝いたします。

物理化学的性質、薬物動態の測定、毒性研究を行っていただきました武田薬品工業株式会社の

皆様に感謝いたします。

109

...